Jacqueline E. Shea - 15 May 2025 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Role: Chief Executive Officer, Director
Signature: /s/ Jacqueline E. Shea
Issuer symbol: INO
Transactions as of: 15 May 2025
Net transactions value: -$15,048
Form type: 4
Filing time: 16 May 2025, 16:08:36 UTC
Previous filing: 12 May 2025
Next filing: 21 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Shea Jacqueline Elizabeth	Chief Executive Officer, Director	660 W. GERMANTOWN PIKE, PLYMOUTH MEETING	/s/ Jacqueline E. Shea	16 May 2025	0001771498

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INO	Common Stock	Options Exercise		+17,744	+36%		67,402	15 May 2025	Direct	F1
transaction	INO	Common Stock	Tax liability	$15,048	-7,717	-11%	$1.95	59,685	15 May 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INO	Restricted Stock Unit	Options Exercise	$0	-17,744	-50%	$0.000000	17,744	15 May 2025	Common Stock	17,744		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,233 restricted stock units is as follows: 17,745 shares vested on May 15, 2024; 17,744 shares vested on May 15, 2025; and 17,744 shares will vest on May 15, 2026. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both.
F2	The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.